rss
Br J Ophthalmol doi:10.1136/bjo.2009.163576

Anti-VEG F agents for diabetic maculopathy

  1. Aysha Salam (aysha_salam{at}yahoo.com),
  2. Joanna DaCosta (dacostajoanna{at}hotmail.co.uk),
  3. Sobha Sivaprasad (senswathi{at}aol.com)
  1. King's College Hospital, London, United Kingdom
  2. King's College Hospital, London, United Kingdom
  3. King's College Hospital, London, United Kingdom
    • Published Online First 24 June 2009

    Abstract

    The management of diabetic macular oedema is changing. The therapeutic armamentarium for DMO includes a new group of drugs that inhibit vascular endothelial growth factor (VEGF). These antiVEGF agents are already being used widely in DMO in clinical practice despite the fact that several phase III trials on these drugs are still underway. There are no established protocols on the use of these agents in DMO but short-term results are appealing. This review provides an update on the use of antiVEGF agents in DMO.

    While intravitreal delivery of antiVEGF agents is a relatively safe procedure, the long-term local and systemic effects of these agents in the diabetic population remain unknown. In this regard, this review also highlights the need for close surveillance of the use of these drugs in this high-risk population.

    This Article

    1. Abstract
    2. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.